Ron Gallemore is an Ophthalmology physician affiliated with Retina Macula Institute. OpenAlex indexes 68 publications with 1,994 citations (h-index 25); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4201 Torrance Blvd
220
Torrance, CA 905034504
Telephone
310-944-9393Registry record last updated 5 Dec 2012.
Clinical trials
- Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Sponsor: Retina Macula Institute
- A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Sponsor: Johns Hopkins University
- Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
Sponsor: Retina Macula Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20253 payments
- Astellas Pharma US IncProgram year20256 payments
- Regeneron Healthcare Solutions, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
82.2%Antineovascularisation agents60.5%Faricimab-svoa100%Part B, office-administered≥39 patientsComplement Inhibitor12.4%Avacincaptad pegol100%Part B, office-administered≥21 patients+ 11 more classes in this area
Cancer & immunology
12.9%Complement Inhibitor9.2%Pegcetacoplan100%Part B, office-administered≥14 patientsVascular Endothelial Growth Factor Inhibitor3.6%Aflibercept100%Part B, office-administered≥60 patients+ 1 more class in this area
Anti-infectives
2.6%Fluoroquinolone Antibacterial2.5%Moxifloxacin100%Part D≥162 patientsMacrolide0.1%Erythromycin100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Combined Central Retinal Artery and Vein Occlusion with Ischemic Optic Neuropathy After COVID-19 Vaccination
DOAJ (DOAJ: Directory of Open Access Journals)
2022 - Visual Snow-Like Symptoms and Posterior Uveitis following COVID-19 Infection
Case Reports in Ophthalmological Medicine
2021 - A Bibliometric Analysis of the Top 100 Cited Papers in Retinal Detachment
Journal of VitreoRetinal Diseases
2021 - Emerging biological therapies for the treatment of age-related macular degeneration
Expert Opinion on Emerging Drugs
2021
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”